Literature DB >> 32091330

Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning.

Yoichi Morofuji1, Shinsuke Nakagawa2.   

Abstract

An important goal of biomedical research is to translate basic research findings into practical clinical implementation. Despite the advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging. The failure rate for new drugs targeting important central nervous system diseases is high compared to most other areas of drug discovery. The main reason for the failure is the poor penetration efficacy across the blood-brain barrier. The blood-brain barrier represents the bottleneck in central nervous system drug development and is the most important factor limiting the future growth of neurotherapeutics. Meanwhile, drug repositioning has been becoming increasingly popular and it seems a promising field in central nervous system drug development. In vitro blood-brain barrier models with high predictability are expected for drug development and drug repositioning. In this review, the recent progress of in vitro BBB models and the drug repositioning for central nervous system diseases will be discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Blood-brain barrier; central nervous system disease; drug development; drug repositioning; neurotherapeutics; penetration efficacy.

Year:  2020        PMID: 32091330     DOI: 10.2174/1381612826666200224112534

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  FTY720 Exacerbates Blood-Brain Barrier Dysfunction Induced by IgG Derived from Patients with NMO and MOG Disease.

Authors:  Shunsuke Yoshimura; Shinsuke Nakagawa; Toshiyuki Takahashi; Keiko Tanaka; Akira Tsujino
Journal:  Neurotox Res       Date:  2021-05-17       Impact factor: 3.911

Review 2.  Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example.

Authors:  Ali S Imami; Robert E McCullumsmith; Sinead M O'Donovan
Journal:  Transl Psychiatry       Date:  2021-11-16       Impact factor: 6.222

Review 3.  Organ-Specific Endothelial Cell Differentiation and Impact of Microenvironmental Cues on Endothelial Heterogeneity.

Authors:  Laia Gifre-Renom; Margo Daems; Aernout Luttun; Elizabeth A V Jones
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

Review 4.  Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer.

Authors:  Yoichi Morofuji; Shinsuke Nakagawa; Kenta Ujifuku; Takashi Fujimoto; Kaishi Otsuka; Masami Niwa; Keisuke Tsutsumi
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-26

5.  A Study on the Application of Extended Care Based on the Biopsychosocial Medicine Model in People with Abnormal Tumor Markers on Physical Examination.

Authors:  Wenting Wang; Chunyu Lin; Hong Yu; Shuai Zhou
Journal:  Contrast Media Mol Imaging       Date:  2022-08-08       Impact factor: 3.009

6.  Defective Function of the Blood-Brain Barrier in a Stroke-Prone Spontaneously Hypertensive Rat: Evaluation in an In Vitro Cell Culture Model.

Authors:  Shinsuke Nakagawa; Hiroki Ohara; Masami Niwa; Kazuo Yamagata; Toru Nabika
Journal:  Cell Mol Neurobiol       Date:  2020-07-09       Impact factor: 5.046

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.